Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

Outcomes with “7+3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escal...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Halpern, Anna B., Othus, Megan, Huebner, Emily M., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Gardner, Kelda M., Chen, Tara L., Buckley, Sarah A., Orlowski, Kaysey F., Anwar, Asma, Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H., Walter, Roland B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192860/
https://ncbi.nlm.nih.gov/pubmed/29720734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0135-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak